Table 2. Open in new tab Selected NS5A...

Patient	Genotype	Previous Treatment	NS5A Mutant (% Population)	NS5B Mutant (% Population)	Outcome
D15	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (1.1%) Y93C (2.0%)	Y93H (1.0%) Y93C (3.9%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D16	1a	LDV/SOF + GS-9669	ND	ND	K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)	>100	N/A	ND	ND	None	N/A	SVR₁₂
D17	1a	LDV/SOF + GS-9451	None	Q30R (28.4%) L31M (70.9%)	Q30R (17.1%) L31M (79.8%)	>100	N/A	None	None	None	N/A	Withdrawn
D18	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D19	1a	LDV/SOF + GS-9451	None	L31M (98.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D20	1a	LDV/SOF + GS-9451	None	Q30H (>99%) Y93H (>99%)	Q30H (>99%) Y93H (97.0%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D21	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D22	1b	LDV/SOF + GS-9451	None	L31V (6.2%) L31M (45.9%) L31I (47.9%)	L31I (31.9%) L31M (67.0%)	>25	N/A	None	None	None	N/A	SVR₁₂
D23	1a	LDV/SOF + GS-9451	None	Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D24	1a	LDV/SOF + GS-9451	None	Q30R (20.1%) L31M (70.8%)	Q30R (3.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D25	1b	LDV/SOF + GS-9451^a	L31M (94.1%)	L31M (>99%) Y93H (>99%)	L31M (>99%) Y93H (28.6%)	>1000	L31M (>99%) Y93H (>99%)	None	None	None	S282T (17.7%) V321I (9.3%)	Relapse
D26	1a	LDV/SOF + GS-9451 + GS-9669	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D27	1a	LDV/SOF + GS-9451	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D28	1b	LDV/SOF + GS-9451 + GS-9669	Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	Withdrawn
D29	1b	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D30	1a	LDV/SOF + GS-9451 + GS-9669	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D31	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)	Q30H (1.2%) Q30R (57.8%) L31M (11.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D32	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (89.2%)	Q30R (4.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D33	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (1.2%) Q30H (22.7%)	Q30R (1.7%) Q30H (60.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D34	1a	LDV/SOF + GS-9451	L31M (65.8%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D35	1a	LDV/SOF + GS-9451 + GS-9669	L31M (14.3%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D36	1a	LDV/SOF + GS-9451 + GS-9669	Y93N (45.0%)	Y93N (>99%)	Y93N (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D37	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.2%)	Q30H (2.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D38	1a	LDV/SOF + GS-9451 + GS-9669	L31M (>99%)	L31M (>99%)	L31M (98.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D39	1b	LDV/SOF + GS-9451 + GS-9669	L31M (8.1%) Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D40	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D41	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D42	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.6%) Q30H (45.9%) Q30R (53.9%)	Q30R (24.9%) Q30H (74.6%)	>100	N/A	None	None	None	N/A	SVR₁₂
D43	1a	LDV/SOF + GS-9451	None	L31M (98.9%)	Q30H (56.1%) L31M (43.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D44	1a	LDV/SOF + GS-9451 + GS-9669	None	K24R (89.5%) L31M (>99%)	K24R (75.6%) L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D45	1a	LDV/SOF + GS-9451 + GS-9669	L31M (1.9%)	L31M (98.9%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D46	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (>99%)	Q30R (8.6%) L31M (26.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D47	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.4%) Q30R (10.9%) L31M (84.4%)	Q30R (1.2%) L31M (98.1%)	>100	N/A	None	None	None	N/A	SVR₁₂
D48	1b	LDV/SOF + GS-9451 + GS-9669	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	>1000	N/A	None	None	L159F (3.1%)	N/A	SVR₁₂

Patient

Genotype

Previous Treatment

NS5A Mutant (% Population)

NS5B Mutant (% Population)

Outcome

Baseline

Relapse

Prior to Retreatment

Relapse

Baseline

Relapse

Prior to Retreatment

Relapse

Resistance-Associated Variants

Fold Resistance

D15

LDV/SOF + GS-9451 + GS-9669

None

Y93H (1.1%) Y93C (2.0%)

Y93H (1.0%) Y93C (3.9%)

>1000

N/A

None

N/A

SVR₁₂

D16

LDV/SOF + GS-9669

K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)

>100

N/A

None

N/A

SVR₁₂

D17

LDV/SOF + GS-9451

None

Q30R (28.4%) L31M (70.9%)

Q30R (17.1%) L31M (79.8%)

>100

N/A

None

N/A

Withdrawn

D18

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D19

LDV/SOF + GS-9451

None

L31M (98.7%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D20

LDV/SOF + GS-9451

None

Q30H (>99%) Y93H (>99%)

Q30H (>99%) Y93H (97.0%)

>1000

N/A

None

N/A

SVR₁₂

D21

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D22

LDV/SOF + GS-9451

None

L31V (6.2%) L31M (45.9%) L31I (47.9%)

L31I (31.9%) L31M (67.0%)

>25

N/A

None

N/A

SVR₁₂

D23

LDV/SOF + GS-9451

None

Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D24

LDV/SOF + GS-9451

None

Q30R (20.1%) L31M (70.8%)

Q30R (3.4%)

>100

N/A

None

N/A

SVR₁₂

D25

LDV/SOF + GS-9451^a

L31M (94.1%)

L31M (>99%) Y93H (>99%)

L31M (>99%) Y93H (28.6%)

>1000

L31M (>99%) Y93H (>99%)

None

S282T (17.7%) V321I (9.3%)

Relapse

D26

LDV/SOF + GS-9451 + GS-9669

None

N/A

None

N/A

SVR₁₂

D27

LDV/SOF + GS-9451

None

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D28

LDV/SOF + GS-9451 + GS-9669

Y93H (>99%)

>1000

N/A

None

N/A

Withdrawn

D29

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D30

LDV/SOF + GS-9451 + GS-9669

None

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D31

LDV/SOF + GS-9451 + GS-9669

None

M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)

Q30H (1.2%) Q30R (57.8%) L31M (11.9%)

>100

N/A

None

N/A

SVR₁₂

D32

LDV/SOF + GS-9451 + GS-9669

None

Q30R (89.2%)

Q30R (4.4%)

>100

N/A

None

N/A

SVR₁₂

D33

LDV/SOF + GS-9451 + GS-9669

None

Q30R (1.2%) Q30H (22.7%)

Q30R (1.7%) Q30H (60.8%)

>100

N/A

None

N/A

SVR₁₂

D34

LDV/SOF + GS-9451

L31M (65.8%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D35

LDV/SOF + GS-9451 + GS-9669

L31M (14.3%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D36

LDV/SOF + GS-9451 + GS-9669

Y93N (45.0%)

Y93N (>99%)

>1000

N/A

None

N/A

SVR₁₂

D37

LDV/SOF + GS-9451 + GS-9669

None

Q30H (1.2%)

Q30H (2.7%)

>100

N/A

None

N/A

SVR₁₂

D38

LDV/SOF + GS-9451 + GS-9669

L31M (>99%)

L31M (98.9%)

>100

N/A

None

N/A

SVR₁₂

D39

LDV/SOF + GS-9451 + GS-9669

L31M (8.1%) Y93H (>99%)

Y93H (>99%)

>1000

N/A

None

N/A

SVR₁₂

D40

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D41

LDV/SOF + GS-9451 + GS-9669

None

Y93H (>99%)

>1000

N/A

None

N/A

SVR₁₂

D42

LDV/SOF + GS-9451 + GS-9669

None

M28T (1.6%) Q30H (45.9%) Q30R (53.9%)

Q30R (24.9%) Q30H (74.6%)

>100

N/A

None

N/A

SVR₁₂

D43

LDV/SOF + GS-9451

None

L31M (98.9%)

Q30H (56.1%) L31M (43.8%)

>100

N/A

None

N/A

SVR₁₂

D44

LDV/SOF + GS-9451 + GS-9669

None

K24R (89.5%) L31M
(>99%)

K24R (75.6%) L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D45

LDV/SOF + GS-9451 + GS-9669

L31M (1.9%)

L31M (98.9%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D46

LDV/SOF + GS-9451 + GS-9669

None

Q30R (>99%)

Q30R (8.6%) L31M (26.7%)

>100

N/A

None

N/A

SVR₁₂

D47

LDV/SOF + GS-9451 + GS-9669

None

Q30H (1.4%) Q30R
(10.9%) L31M (84.4%)

Q30R (1.2%) L31M (98.1%)

>100

N/A

None

N/A

SVR₁₂

D48

LDV/SOF + GS-9451 + GS-9669

Q30T (>99%) L31V (>99%) Y93H (>99%)

Q30T (>99%) L31V
(>99%) Y93H (>99%)

Q30T (>99%) L31V (>99%) Y93H (>99%)

>1000

N/A

None

L159F (3.1%)

N/A

SVR₁₂

Patient	Genotype	Previous Treatment	NS5A Mutant (% Population)	NS5B Mutant (% Population)	Outcome
D15	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (1.1%) Y93C (2.0%)	Y93H (1.0%) Y93C (3.9%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D16	1a	LDV/SOF + GS-9669	ND	ND	K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)	>100	N/A	ND	ND	None	N/A	SVR₁₂
D17	1a	LDV/SOF + GS-9451	None	Q30R (28.4%) L31M (70.9%)	Q30R (17.1%) L31M (79.8%)	>100	N/A	None	None	None	N/A	Withdrawn
D18	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D19	1a	LDV/SOF + GS-9451	None	L31M (98.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D20	1a	LDV/SOF + GS-9451	None	Q30H (>99%) Y93H (>99%)	Q30H (>99%) Y93H (97.0%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D21	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D22	1b	LDV/SOF + GS-9451	None	L31V (6.2%) L31M (45.9%) L31I (47.9%)	L31I (31.9%) L31M (67.0%)	>25	N/A	None	None	None	N/A	SVR₁₂
D23	1a	LDV/SOF + GS-9451	None	Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D24	1a	LDV/SOF + GS-9451	None	Q30R (20.1%) L31M (70.8%)	Q30R (3.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D25	1b	LDV/SOF + GS-9451^a	L31M (94.1%)	L31M (>99%) Y93H (>99%)	L31M (>99%) Y93H (28.6%)	>1000	L31M (>99%) Y93H (>99%)	None	None	None	S282T (17.7%) V321I (9.3%)	Relapse
D26	1a	LDV/SOF + GS-9451 + GS-9669	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D27	1a	LDV/SOF + GS-9451	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D28	1b	LDV/SOF + GS-9451 + GS-9669	Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	Withdrawn
D29	1b	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D30	1a	LDV/SOF + GS-9451 + GS-9669	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D31	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)	Q30H (1.2%) Q30R (57.8%) L31M (11.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D32	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (89.2%)	Q30R (4.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D33	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (1.2%) Q30H (22.7%)	Q30R (1.7%) Q30H (60.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D34	1a	LDV/SOF + GS-9451	L31M (65.8%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D35	1a	LDV/SOF + GS-9451 + GS-9669	L31M (14.3%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D36	1a	LDV/SOF + GS-9451 + GS-9669	Y93N (45.0%)	Y93N (>99%)	Y93N (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D37	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.2%)	Q30H (2.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D38	1a	LDV/SOF + GS-9451 + GS-9669	L31M (>99%)	L31M (>99%)	L31M (98.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D39	1b	LDV/SOF + GS-9451 + GS-9669	L31M (8.1%) Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D40	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D41	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D42	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.6%) Q30H (45.9%) Q30R (53.9%)	Q30R (24.9%) Q30H (74.6%)	>100	N/A	None	None	None	N/A	SVR₁₂
D43	1a	LDV/SOF + GS-9451	None	L31M (98.9%)	Q30H (56.1%) L31M (43.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D44	1a	LDV/SOF + GS-9451 + GS-9669	None	K24R (89.5%) L31M (>99%)	K24R (75.6%) L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D45	1a	LDV/SOF + GS-9451 + GS-9669	L31M (1.9%)	L31M (98.9%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D46	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (>99%)	Q30R (8.6%) L31M (26.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D47	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.4%) Q30R (10.9%) L31M (84.4%)	Q30R (1.2%) L31M (98.1%)	>100	N/A	None	None	None	N/A	SVR₁₂
D48	1b	LDV/SOF + GS-9451 + GS-9669	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	>1000	N/A	None	None	L159F (3.1%)	N/A	SVR₁₂

Patient

Genotype

Previous Treatment

NS5A Mutant (% Population)

NS5B Mutant (% Population)

Outcome

Baseline

Relapse

Prior to Retreatment

Relapse

Baseline

Relapse

Prior to Retreatment

Relapse

Resistance-Associated Variants

Fold Resistance

D15

LDV/SOF + GS-9451 + GS-9669

None

Y93H (1.1%) Y93C (2.0%)

Y93H (1.0%) Y93C (3.9%)

>1000

N/A

None

N/A

SVR₁₂

D16

LDV/SOF + GS-9669

K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)

>100

N/A

None

N/A

SVR₁₂

D17

LDV/SOF + GS-9451

None

Q30R (28.4%) L31M (70.9%)

Q30R (17.1%) L31M (79.8%)

>100

N/A

None

N/A

Withdrawn

D18

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D19

LDV/SOF + GS-9451

None

L31M (98.7%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D20

LDV/SOF + GS-9451

None

Q30H (>99%) Y93H (>99%)

Q30H (>99%) Y93H (97.0%)

>1000

N/A

None

N/A

SVR₁₂

D21

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D22

LDV/SOF + GS-9451

None

L31V (6.2%) L31M (45.9%) L31I (47.9%)

L31I (31.9%) L31M (67.0%)

>25

N/A

None

N/A

SVR₁₂

D23

LDV/SOF + GS-9451

None

Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D24

LDV/SOF + GS-9451

None

Q30R (20.1%) L31M (70.8%)

Q30R (3.4%)

>100

N/A

None

N/A

SVR₁₂

D25

LDV/SOF + GS-9451^a

L31M (94.1%)

L31M (>99%) Y93H (>99%)

L31M (>99%) Y93H (28.6%)

>1000

L31M (>99%) Y93H (>99%)

None

S282T (17.7%) V321I (9.3%)

Relapse

D26

LDV/SOF + GS-9451 + GS-9669

None

N/A

None

N/A

SVR₁₂

D27

LDV/SOF + GS-9451

None

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D28

LDV/SOF + GS-9451 + GS-9669

Y93H (>99%)

>1000

N/A

None

N/A

Withdrawn

D29

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D30

LDV/SOF + GS-9451 + GS-9669

None

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D31

LDV/SOF + GS-9451 + GS-9669

None

M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)

Q30H (1.2%) Q30R (57.8%) L31M (11.9%)

>100

N/A

None

N/A

SVR₁₂

D32

LDV/SOF + GS-9451 + GS-9669

None

Q30R (89.2%)

Q30R (4.4%)

>100

N/A

None

N/A

SVR₁₂

D33

LDV/SOF + GS-9451 + GS-9669

None

Q30R (1.2%) Q30H (22.7%)

Q30R (1.7%) Q30H (60.8%)

>100

N/A

None

N/A

SVR₁₂

D34

LDV/SOF + GS-9451

L31M (65.8%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D35

LDV/SOF + GS-9451 + GS-9669

L31M (14.3%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D36

LDV/SOF + GS-9451 + GS-9669

Y93N (45.0%)

Y93N (>99%)

>1000

N/A

None

N/A

SVR₁₂

D37

LDV/SOF + GS-9451 + GS-9669

None

Q30H (1.2%)

Q30H (2.7%)

>100

N/A

None

N/A

SVR₁₂

D38

LDV/SOF + GS-9451 + GS-9669

L31M (>99%)

L31M (98.9%)

>100

N/A

None

N/A

SVR₁₂

D39

LDV/SOF + GS-9451 + GS-9669

L31M (8.1%) Y93H (>99%)

Y93H (>99%)

>1000

N/A

None

N/A

SVR₁₂

D40

LDV/SOF + GS-9451

None

N/A

None

N/A

SVR₁₂

D41

LDV/SOF + GS-9451 + GS-9669

None

Y93H (>99%)

>1000

N/A

None

N/A

SVR₁₂

D42

LDV/SOF + GS-9451 + GS-9669

None

M28T (1.6%) Q30H (45.9%) Q30R (53.9%)

Q30R (24.9%) Q30H (74.6%)

>100

N/A

None

N/A

SVR₁₂

D43

LDV/SOF + GS-9451

None

L31M (98.9%)

Q30H (56.1%) L31M (43.8%)

>100

N/A

None

N/A

SVR₁₂

D44

LDV/SOF + GS-9451 + GS-9669

None

K24R (89.5%) L31M
(>99%)

K24R (75.6%) L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D45

LDV/SOF + GS-9451 + GS-9669

L31M (1.9%)

L31M (98.9%)

L31M (>99%)

>100

N/A

None

N/A

SVR₁₂

D46

LDV/SOF + GS-9451 + GS-9669

None

Q30R (>99%)

Q30R (8.6%) L31M (26.7%)

>100

N/A

None

N/A

SVR₁₂

D47

LDV/SOF + GS-9451 + GS-9669

None

Q30H (1.4%) Q30R
(10.9%) L31M (84.4%)

Q30R (1.2%) L31M (98.1%)

>100

N/A

None

N/A

SVR₁₂

D48

LDV/SOF + GS-9451 + GS-9669

Q30T (>99%) L31V (>99%) Y93H (>99%)

Q30T (>99%) L31V
(>99%) Y93H (>99%)

Q30T (>99%) L31V (>99%) Y93H (>99%)

>1000

N/A

None

L159F (3.1%)

N/A

SVR₁₂

Table 2.

Open in new tab

Selected NS5A and NS5B Resistance-Associated Variants by Study Participant

Patient	Genotype	Previous Treatment	NS5A Mutant (% Population)					NS5B Mutant (% Population)				Outcome
			Baseline	Relapse	Prior to Retreatment		Relapse	Baseline	Relapse	Prior to Retreatment	Relapse
			Baseline	Relapse	Resistance-Associated Variants	Fold Resistance	Relapse	Baseline	Relapse	Prior to Retreatment	Relapse
D15	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (1.1%) Y93C (2.0%)	Y93H (1.0%) Y93C (3.9%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D16	1a	LDV/SOF + GS-9669	ND	ND	K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)	>100	N/A	ND	ND	None	N/A	SVR₁₂
D17	1a	LDV/SOF + GS-9451	None	Q30R (28.4%) L31M (70.9%)	Q30R (17.1%) L31M (79.8%)	>100	N/A	None	None	None	N/A	Withdrawn
D18	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D19	1a	LDV/SOF + GS-9451	None	L31M (98.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D20	1a	LDV/SOF + GS-9451	None	Q30H (>99%) Y93H (>99%)	Q30H (>99%) Y93H (97.0%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D21	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D22	1b	LDV/SOF + GS-9451	None	L31V (6.2%) L31M (45.9%) L31I (47.9%)	L31I (31.9%) L31M (67.0%)	>25	N/A	None	None	None	N/A	SVR₁₂
D23	1a	LDV/SOF + GS-9451	None	Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D24	1a	LDV/SOF + GS-9451	None	Q30R (20.1%) L31M (70.8%)	Q30R (3.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D25	1b	LDV/SOF + GS-9451^a	L31M (94.1%)	L31M (>99%) Y93H (>99%)	L31M (>99%) Y93H (28.6%)	>1000	L31M (>99%) Y93H (>99%)	None	None	None	S282T (17.7%) V321I (9.3%)	Relapse
D26	1a	LDV/SOF + GS-9451 + GS-9669	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D27	1a	LDV/SOF + GS-9451	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D28	1b	LDV/SOF + GS-9451 + GS-9669	Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	Withdrawn
D29	1b	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D30	1a	LDV/SOF + GS-9451 + GS-9669	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D31	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)	Q30H (1.2%) Q30R (57.8%) L31M (11.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D32	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (89.2%)	Q30R (4.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D33	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (1.2%) Q30H (22.7%)	Q30R (1.7%) Q30H (60.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D34	1a	LDV/SOF + GS-9451	L31M (65.8%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D35	1a	LDV/SOF + GS-9451 + GS-9669	L31M (14.3%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D36	1a	LDV/SOF + GS-9451 + GS-9669	Y93N (45.0%)	Y93N (>99%)	Y93N (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D37	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.2%)	Q30H (2.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D38	1a	LDV/SOF + GS-9451 + GS-9669	L31M (>99%)	L31M (>99%)	L31M (98.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D39	1b	LDV/SOF + GS-9451 + GS-9669	L31M (8.1%) Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D40	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D41	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D42	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.6%) Q30H (45.9%) Q30R (53.9%)	Q30R (24.9%) Q30H (74.6%)	>100	N/A	None	None	None	N/A	SVR₁₂
D43	1a	LDV/SOF + GS-9451	None	L31M (98.9%)	Q30H (56.1%) L31M (43.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D44	1a	LDV/SOF + GS-9451 + GS-9669	None	K24R (89.5%) L31M (>99%)	K24R (75.6%) L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D45	1a	LDV/SOF + GS-9451 + GS-9669	L31M (1.9%)	L31M (98.9%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D46	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (>99%)	Q30R (8.6%) L31M (26.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D47	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.4%) Q30R (10.9%) L31M (84.4%)	Q30R (1.2%) L31M (98.1%)	>100	N/A	None	None	None	N/A	SVR₁₂
D48	1b	LDV/SOF + GS-9451 + GS-9669	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	>1000	N/A	None	None	L159F (3.1%)	N/A	SVR₁₂

Patient	Genotype	Previous Treatment	NS5A Mutant (% Population)					NS5B Mutant (% Population)				Outcome
			Baseline	Relapse	Prior to Retreatment		Relapse	Baseline	Relapse	Prior to Retreatment	Relapse
			Baseline	Relapse	Resistance-Associated Variants	Fold Resistance	Relapse	Baseline	Relapse	Prior to Retreatment	Relapse
D15	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (1.1%) Y93C (2.0%)	Y93H (1.0%) Y93C (3.9%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D16	1a	LDV/SOF + GS-9669	ND	ND	K24R (8.0%) M28T (75.0%) Q30L (24.5%) Q30H (74.4%)	>100	N/A	ND	ND	None	N/A	SVR₁₂
D17	1a	LDV/SOF + GS-9451	None	Q30R (28.4%) L31M (70.9%)	Q30R (17.1%) L31M (79.8%)	>100	N/A	None	None	None	N/A	Withdrawn
D18	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D19	1a	LDV/SOF + GS-9451	None	L31M (98.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D20	1a	LDV/SOF + GS-9451	None	Q30H (>99%) Y93H (>99%)	Q30H (>99%) Y93H (97.0%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D21	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D22	1b	LDV/SOF + GS-9451	None	L31V (6.2%) L31M (45.9%) L31I (47.9%)	L31I (31.9%) L31M (67.0%)	>25	N/A	None	None	None	N/A	SVR₁₂
D23	1a	LDV/SOF + GS-9451	None	Q30R (10.5%) Q30K (13.1%) L31V (2.3%) L31M (74.7%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D24	1a	LDV/SOF + GS-9451	None	Q30R (20.1%) L31M (70.8%)	Q30R (3.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D25	1b	LDV/SOF + GS-9451^a	L31M (94.1%)	L31M (>99%) Y93H (>99%)	L31M (>99%) Y93H (28.6%)	>1000	L31M (>99%) Y93H (>99%)	None	None	None	S282T (17.7%) V321I (9.3%)	Relapse
D26	1a	LDV/SOF + GS-9451 + GS-9669	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D27	1a	LDV/SOF + GS-9451	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D28	1b	LDV/SOF + GS-9451 + GS-9669	Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	Withdrawn
D29	1b	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D30	1a	LDV/SOF + GS-9451 + GS-9669	None	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D31	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.4%) Q30H (2.6%) Q30R (56.8%) L31M (34.3%) S38F (2.3%)	Q30H (1.2%) Q30R (57.8%) L31M (11.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D32	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (89.2%)	Q30R (4.4%)	>100	N/A	None	None	None	N/A	SVR₁₂
D33	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (1.2%) Q30H (22.7%)	Q30R (1.7%) Q30H (60.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D34	1a	LDV/SOF + GS-9451	L31M (65.8%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D35	1a	LDV/SOF + GS-9451 + GS-9669	L31M (14.3%)	L31M (>99%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D36	1a	LDV/SOF + GS-9451 + GS-9669	Y93N (45.0%)	Y93N (>99%)	Y93N (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D37	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.2%)	Q30H (2.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D38	1a	LDV/SOF + GS-9451 + GS-9669	L31M (>99%)	L31M (>99%)	L31M (98.9%)	>100	N/A	None	None	None	N/A	SVR₁₂
D39	1b	LDV/SOF + GS-9451 + GS-9669	L31M (8.1%) Y93H (>99%)	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D40	1a	LDV/SOF + GS-9451	None	None	None	N/A	N/A	None	None	None	N/A	SVR₁₂
D41	1b	LDV/SOF + GS-9451 + GS-9669	None	Y93H (>99%)	Y93H (>99%)	>1000	N/A	None	None	None	N/A	SVR₁₂
D42	1a	LDV/SOF + GS-9451 + GS-9669	None	M28T (1.6%) Q30H (45.9%) Q30R (53.9%)	Q30R (24.9%) Q30H (74.6%)	>100	N/A	None	None	None	N/A	SVR₁₂
D43	1a	LDV/SOF + GS-9451	None	L31M (98.9%)	Q30H (56.1%) L31M (43.8%)	>100	N/A	None	None	None	N/A	SVR₁₂
D44	1a	LDV/SOF + GS-9451 + GS-9669	None	K24R (89.5%) L31M (>99%)	K24R (75.6%) L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D45	1a	LDV/SOF + GS-9451 + GS-9669	L31M (1.9%)	L31M (98.9%)	L31M (>99%)	>100	N/A	None	None	None	N/A	SVR₁₂
D46	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30R (>99%)	Q30R (8.6%) L31M (26.7%)	>100	N/A	None	None	None	N/A	SVR₁₂
D47	1a	LDV/SOF + GS-9451 + GS-9669	None	Q30H (1.4%) Q30R (10.9%) L31M (84.4%)	Q30R (1.2%) L31M (98.1%)	>100	N/A	None	None	None	N/A	SVR₁₂
D48	1b	LDV/SOF + GS-9451 + GS-9669	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	Q30T (>99%) L31V (>99%) Y93H (>99%)	>1000	N/A	None	None	L159F (3.1%)	N/A	SVR₁₂

Abbreviations: LDV, ledipasvir; N/A, not applicable; ND, not done; SOF, sofosbuvir; SVR, sustained virological response.

^a Received therapy for 6 weeks; all others treated for 4 weeks.

This Feature Is Available To Subscribers Only